Current status of anti-angiogenic agents in the treatment of ovarian carcinoma

Clinical and Translational Oncology

Volumn 11, Issue 9, 2009, Pages 589-595

  Sánchez Muñoz, Alfonso ^a   Pérez Ruiz, Elisabeth ^b   Fernández, César Mendiola ^a   Conejo, Emilio Alba ^c   González Martín, Antonio ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Antiangiogenic agents; Bevacizumab; Ovarian cancer; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ALGORITHM; CARCINOMA; CONFLICT; EVALUATION; FEMALE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; RECURRENT DISEASE; REVIEW; VASCULARIZATION;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISSENT AND DISPUTES; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RECURRENCE;

EID: 73349083412     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0409-8     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer Statistics 2009. CA Cancer J Clin 59:225-249
2. Harries M, Gore M (2002) Part I: Chemotherapy for epithelial ovarian cancer treatment as first diagnosis. Lancet Oncol 3:529-536
3. Frumovitz M, Sood AK (2007) Vascular endothelial growth factor pathway as a target in gynecologic cancer malignancies. Gynecol Oncol 104:768-778
4. Ellis L, Fidler I (1996) Angiogenesis and metastasis. Eur J Cancer 32A:2451-2460
5. Bamberger ES, Perret CW (2002) Angiogenesis in epithelial ovarian cancer. Mol Pathol 55:348-359
6. Byrne AT, Ross L, Holash J et al (2003) VEGFtrap decreases tumor burden, inhibits ascites and causes dramatic vascular remodeling in an ovarian cancer. Clin Cancer Res 9:5721-5728
7. Monk BJ, Choi DC, Pugmire G, Burger RA (2005) Activity of bevacizumab in advanced refractory epithelial ovarian cancer. Gynecol Oncol 96:902-905
8. Cohn DE, Valmadre S, Resnick KE et al (2006) Bevacizumab and weekly taxane chemotherapy demonstrate activity in refractory ovarian cancer. Gynecol Oncol 102:134-139
9. Monk BJ, Han E, Josephs-Cowan CA et al (2006) Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102:140-144
10. Wright JD, Hagemann A, Rader JS et al (2006) Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 107:83-89
11. Richardson DL, Backes FJ, Seamon LG et al (2008) Combination gemcitabine, platinum and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 111:461-466
12. Burger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171
13. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platin-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186
14. Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76-82
15. Jurado JM, Sánchez-Muñoz A, Pajares B et al (2008) Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 10:583-586
16. Nimeiri HS, Oza AM, Morgan RJ et al (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago PMH, and California phase II consortia. Gynecol Oncol 110:49-55
17. McGonigle KF, Muntz HG, Vuky JL et al (2008) Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer. J Clin Oncol 26[Suppl]:abstr 5551
18. Penson RT, Cannistra SA, Seiden MV et al (2006) Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. J Clin Oncol 24[18 Suppl]:260s (abstr 5020)
19. Campos SM, Dizon DS, Cannistra SA et al (2007) Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers. J Clin Oncol 25[18 Suppl]:278s (abstr 5517)
20. Herzog TJ, Spirtos NM, Hines JF et al (2007) Preliminary safety and efficacy results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum and fallopian tube. J Clin Oncol 25[18 Suppl]:278s (abstr 5518)
21. Konner JA, Fallon K, Pezzuli S et al (2007) A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol 25[18 Suppl]:279s (abstr 5523)
22. Casanovas O, Hickling DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF-signalling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309
23. Tew WP, Colombo N, Ray-Coquard I et al (2007) VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 25[18 Suppl]:5508
24. Welch S, Hirte H, Schilder RJ et al (2006) Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. J Clin Oncol 24[Suppl]: Abstr 5084
25. Matei D, Sill MW, DeGeest K, Bristow RE (2008) Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 26[Suppl]:abstr 5537
26. Azad NS, Jain L, Annunziata C (2008) Correlative studies of a phase I trial of combination anti-vascular endothelial growth factor (VEGF) therapy with sorafenib and bevacizumab. J Clin Oncol 26[Suppl]:abstr 3545
27. Biagi JJ, Oza AM, Grimshaw R et al (2008) A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma-NCIC CTG IND 185. J Clin Oncol 26[Suppl]:abstr 5522
28. Friedlander M, Hancock KC, Benigno B et al (2007) Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study. J Clin Oncol 25[Suppl]:abstr 5561
29. Hirte HW, Vidal L, Fleming GF et al (2008) A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Fi nal results of a PMH, Chicago and California consortia trial. J Clin Oncol 26[Suppl]:abstr 5521
30. Matulonis UA, Berlin ST, Krasner CN et al (2008) Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 26[Suppl]:abstr 5501